--- title: 'Regulatory Daily Summary: What Happened on November 1, 2026' headline: FDA proposes one-application framework for individualized gene editing description: Draft guidance covers product variation and postapproval oversight for treatments targeting rare genetic diseases. url: https://thebench.bio/news/regulatory/2026-11-01 topic: regulatory date: '2026-11-01' covers: - '2026-11-01' date_published: '2026-11-02T00:00:52Z' date_modified: '2026-11-02T00:00:52Z' tags: - Regulatory sources: 1 publisher: TheBench.Bio --- # Regulatory Daily Summary: What Happened on November 1, 2026 **FDA proposes one-application framework for individualized gene editing** Draft guidance covers product variation and postapproval oversight for treatments targeting rare genetic diseases. ## Today in brief The FDA's proposed review framework could allow developers to make some product changes within a single biologics license application for individualized genome-editing treatments. [1] Public comments are open through November 27. [1] ## Draft guidance would set bounds for product changes The FDA issued draft guidance on October 27 covering applications and postapproval oversight for individualized genome-editing products targeting rare genetic diseases. [1] It proposes an “Individualized Feature Space” to define permissible product variation within one biologics license application, potentially allowing changes within those bounds without additional trials. [1] The agency is accepting public comments through November 27. [1] ## The day in numbers - **November 27**: Deadline for comments on the FDA's draft guidance. [1] ## Also published - [The Flexibility Papers, No. 2: Beyond Listening—Making Patient Input Matter](), FDA Law Blog ## Sources 1. [StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance](), GEN, 2026-11-01 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: